Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

Cited In for PubMed (Select 17940966)

1.

Probing the virus host interaction in high containment: an approach using pooled short hairpin RNA.

Filone CM, Dower K, Cowley GS, Hensley LE, Connor JH.

Assay Drug Dev Technol. 2015 Jan-Feb;13(1):34-43. doi: 10.1089/adt.2014.613. Epub 2015 Feb 3.

PMID:
25646658
2.

A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity.

Watt A, Moukambi F, Banadyga L, Groseth A, Callison J, Herwig A, Ebihara H, Feldmann H, Hoenen T.

J Virol. 2014 Sep;88(18):10511-24. doi: 10.1128/JVI.01272-14. Epub 2014 Jun 25.

3.

Development and application of reporter-expressing mononegaviruses: current challenges and perspectives.

Falzarano D, Groseth A, Hoenen T.

Antiviral Res. 2014 Mar;103:78-87. doi: 10.1016/j.antiviral.2014.01.003. Epub 2014 Jan 23. Review.

4.

Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA.

Kuhn JH, Bào Y, Bavari S, Becker S, Bradfute S, Brauburger K, Rodney Brister J, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Arch Virol. 2014 May;159(5):1229-37. doi: 10.1007/s00705-013-1877-2. Epub 2013 Nov 5.

5.

FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG.

Sci Transl Med. 2013 Jun 19;5(190):190ra79. doi: 10.1126/scitranslmed.3005471.

6.

A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals.

Hoenen T, Groseth A, Callison J, Takada A, Feldmann H.

Antiviral Res. 2013 Sep;99(3):207-13. doi: 10.1016/j.antiviral.2013.05.017. Epub 2013 Jun 7.

7.

Ebola virus does not block apoptotic signaling pathways.

Olejnik J, Alonso J, Schmidt KM, Yan Z, Wang W, Marzi A, Ebihara H, Yang J, Patterson JL, Ryabchikova E, Mühlberger E.

J Virol. 2013 May;87(10):5384-96. doi: 10.1128/JVI.01461-12. Epub 2013 Mar 6.

8.

Inclusion bodies are a site of ebolavirus replication.

Hoenen T, Shabman RS, Groseth A, Herwig A, Weber M, Schudt G, Dolnik O, Basler CF, Becker S, Feldmann H.

J Virol. 2012 Nov;86(21):11779-88. doi: 10.1128/JVI.01525-12. Epub 2012 Aug 22.

9.

Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection.

Miller ME, Adhikary S, Kolokoltsov AA, Davey RA.

J Virol. 2012 Jul;86(14):7473-83. doi: 10.1128/JVI.00136-12. Epub 2012 May 9.

10.

Evaluation of perceived threat differences posed by filovirus variants.

Kuhn JH, Dodd LE, Wahl-Jensen V, Radoshitzky SR, Bavari S, Jahrling PB.

Biosecur Bioterror. 2011 Dec;9(4):361-71. doi: 10.1089/bsp.2011.0051. Epub 2011 Nov 9.

11.

Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis.

Aleksandrowicz P, Marzi A, Biedenkopf N, Beimforde N, Becker S, Hoenen T, Feldmann H, Schnittler HJ.

J Infect Dis. 2011 Nov;204 Suppl 3:S957-67. doi: 10.1093/infdis/jir326.

12.

Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread.

Schmidt KM, Schümann M, Olejnik J, Krähling V, Mühlberger E.

J Infect Dis. 2011 Nov;204 Suppl 3:S861-70. doi: 10.1093/infdis/jir308.

13.

Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.

Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H.

J Infect Dis. 2011 Nov;204 Suppl 3:S1066-74. doi: 10.1093/infdis/jir348.

14.

Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses.

Hoenen T, Groseth A, de Kok-Mercado F, Kuhn JH, Wahl-Jensen V.

Antiviral Res. 2011 Aug;91(2):195-208. doi: 10.1016/j.antiviral.2011.06.003. Epub 2011 Jun 14. Review.

15.

Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies.

de Wit E, Feldmann H, Munster VJ.

Genome Med. 2011 Jan 27;3(1):5. doi: 10.1186/gm219.

16.

Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes.

Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA.

PLoS Pathog. 2010 Sep 16;6(9):e1001110. doi: 10.1371/journal.ppat.1001110.

17.

Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses.

Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, Ströher U, Feldmann H, Jones SM.

PLoS One. 2009;4(5):e5547. doi: 10.1371/journal.pone.0005547. Epub 2009 May 14.

18.

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.

Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, Feldmann H, Kobinger GP.

PLoS One. 2009;4(4):e5308. doi: 10.1371/journal.pone.0005308. Epub 2009 Apr 23.

19.

Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway.

Strong JE, Wong G, Jones SE, Grolla A, Theriault S, Kobinger GP, Feldmann H.

Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17982-7. doi: 10.1073/pnas.0809698105. Epub 2008 Nov 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk